Human Genome sets Lupus drug sales goal
January 10, 2011 at 22:20 PM EST
Chief Executive Tom Watkins says Human Genome Sciences Inc. expects its yet-to-be-approved Lupus drug Benlysta to help generate “multi-billion dollar annual revenues” for the company by 2015.
